Biogen Inc
NASDAQ: BIIB · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Updated 2026-06-05
Biogen Inc (BIIB) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.55B | $8.63B | $8.48B | $8.55B | $8.09B | $9.05B | $10.13B | $11.86B | $14.32B | $19.50B | $22.88B | $23.65B | $25.29B | $27.23B | $24.62B | $23.88B | $24.55B | $26.84B | $28.05B | $29.44B |
| Cash & equivalents | $661.38M | $659.66M | $622.38M | $581.89M | $759.60M | $514.54M | $570.72M | $602.56M | $1.20B | $1.31B | $2.33B | $1.57B | $1.22B | $2.91B | $1.33B | $2.26B | $3.42B | $1.05B | $2.38B | $3.01B |
| Current assets | $1.71B | $2.37B | $2.46B | $2.48B | $2.54B | $2.98B | $3.24B | $3.18B | $4.67B | $6.70B | $8.73B | $7.87B | $7.64B | $8.38B | $6.89B | $7.86B | $9.79B | $6.86B | $7.46B | $8.97B |
| Total liabilities | $1.40B | $3.09B | $2.67B | $2.29B | $2.64B | $2.62B | $3.17B | $3.24B | $3.50B | $10.13B | $10.75B | $11.05B | $12.26B | $13.90B | $13.93B | $12.92B | $11.17B | $12.05B | $11.33B | $11.18B |
| Current liabilities | $582.86M | $2.19B | $923.22M | $714.94M | $1.05B | $912.89M | $1.66B | $1.76B | $2.22B | $2.58B | $3.34B | $3.37B | $3.30B | $4.86B | $3.74B | $4.30B | $3.27B | $3.43B | $5.53B | $3.35B |
| Long-term debt | $96.69M | $51.84M | $1.09B | $1.08B | $1.07B | $1.06B | $687.40M | $592.43M | $582.06M | $6.52B | $6.51B | $5.93B | $5.94B | $4.46B | $7.43B | $6.27B | $6.28B | $6.79B | $4.55B | $6.29B |
| Shareholder equity | $7.15B | $5.53B | $5.81B | $6.22B | $5.40B | $6.43B | $6.96B | $8.62B | $10.81B | $9.37B | $12.13B | $12.60B | $13.04B | $13.34B | $10.70B | $10.90B | $13.40B | $14.80B | $16.72B | $18.26B |
| Retained earnings | $-860.83M | $-352.17M | $270.18M | $1.07B | $1.87B | $3.11B | $4.49B | $6.35B | $9.28B | $12.21B | $15.07B | $15.81B | $16.26B | $16.46B | $13.98B | $13.91B | $16.47B | $17.63B | $19.26B | $20.55B |
| Accounts receivable | $539.36M | $595.73M | $667.09M | $760.90M | $839.99M | $831.23M | $955.24M | $1.08B | $1.58B | $1.23B | $1.44B | $1.79B | $2.49B | $2.47B | $2.33B | $1.96B | $2.14B | $2.10B | $1.87B | $1.87B |
| Inventory | $169.10M | $233.99M | $263.60M | $293.95M | $289.07M | $326.84M | $447.37M | $659.00M | $804.02M | $893.40M | $1.00B | $902.70M | $929.90M | $804.20M | $1.07B | $1.35B | $1.34B | $2.53B | $2.46B | $2.17B |
| Goodwill | $1.15B | $1.14B | $1.14B | $1.14B | $1.15B | $1.15B | $1.20B | $1.23B | $1.76B | $2.66B | $3.67B | $4.63B | $5.71B | $5.76B | $5.76B | $5.76B | $5.75B | $6.22B | $6.48B | $6.49B |
Frequently asked questions
What is Biogen Inc's revenue?
Biogen Inc's trailing twelve-month revenue is $9.94B, and consensus projects about $13.80B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is BIIB?
In its most recent fiscal year, BIIB ran a gross margin of 70.47%, an operating margin of 19.14%, and a net margin of 13.18%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does BIIB generate?
BIIB produced $2.05B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BIIB's balance sheet healthy?
BIIB holds $3.01B in cash and equivalents against $6.29B in long-term debt, on $18.26B of shareholder equity. That debt is best read against the cash flow the business throws off each year.